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ScienceDirectGlucagon-like peptide-1 (GLP-1) is both a peripherally
expressed incretin and a centrally active neuropeptide. Brain
derived GLP-1, produced in preproglucagon (PPG) neurons
located in the nucleus of the solitary tract (NTS) and projecting
to numerous brain regions, is ideally placed to activate central
GLP-1 receptors in a range of autonomic control areas. In vivo
analysis of central GLP-1 using GLP-1 receptor antagonists
has demonstrated the control of a range of feeding responses
mediated by GLP-1 receptor activation. Recent advances
enabling identification and targeting of the neurons in the NTS
has specifically implicated PPG neurons at the core of GLP-1
dependent central and peripheral control for short-term and
long-term energy balance.
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Introduction
‘Gut hormones’ have increasingly been implicated in
brain function [1,2]. One such example is glucagon-like
peptide-1 (GLP-1), which in addition to being gut-
derived, is also synthesised by preproglucagon (PPG)
neurones in the brain. These are located primarily in a
discrete region of the lower brainstem [3]. This review
focuses on the recent advances in our understanding of
the physiological significance of this cell population.
The vast majority of studies examining central GLP-1
effects have been performed on rodents and con-
sequently we will focus on these. Although a small
number of studies on the GLP-1 system have highlighted
differences between mouse and rat [4,5] for most aspects
they appear to be equivalent, and in this review we have
treated studies on either as comparable. Furthermore,
given that the amino acid sequence of GLP-1 is con-
served throughout mammalian species [6] and that the
Open access under CC BY license.Current Opinion in Pharmacology 2013, 13:964–969 distribution of PPG neurons in the non-human primate
Macaca mulatta [7] is strikingly similar to that in rodents
we make the assumption that most of these findings have
clear relevance for GLP-1 action in man.
At present it is still controversial as to how the central
GLP-1 system is linked to peripheral post-prandial GLP-
1 release and whether gut-derived GLP-1 can enter the
brain to a sufficient extent to activate central GLP-1
receptors (reviewed in [3,8,9]). Here, we will not address
these issues, but consider the GLP-1 producing neurons
as an independent cell population and examine the
evidence as to the feasibility of the hypothesis that this
cell population is the principal physiological source of
endogenous GLP-1 interacting with GLP-1 receptors
within the CNS. For this to be the case, there has to
be anatomical evidence that the distribution of PPG cell
axons and GLP-1 release sites matches the distribution of
GLP-1 receptors in brain, functional evidence of
endogenous release of GLP-1 within the CNS, and proof
that inhibition or destruction of these PPG neurons pre-
vents the central effects attributed to GLP-1. We
examine these points in sequence.
Anatomical correlation between GLP-1 receptor
expression and the distribution and projections of PPG
neurons in the brain
It has been known for more than 20 years that GLP-1 is
synthesised in mammalian brain [10–13]. Most published
reports analysing the distribution of PPG neurons are
from rat using either immunocytochemistry for GLP-1 or
GLP-2 [3,10,14–16] or in situ hybridisation [17] to localise
these neurons and their axon terminals. These studies
demonstrated that PPG neurons are non-adrenergic
neurons with their cell bodies located exclusively in
the caudal nucleus of the solitary tract (NTS), the caudal
medullary reticular formation and the olfactory bulb
[14,17]. They also demonstrated a widespread projection
pattern for these neurons with the highest density of
terminals observed in the paraventricular nucleus
(PVN) and the dorsomedial hypothalamus (DMH)
[14,15,18]. Merchenthaler and colleagues [17] also con-
cluded that all GLP-1 terminals outside the olfactory bulb
must originate from the brainstem nuclei, because the
olfactory bulb PPG neurons were located periglomerular,
and were thus local interneurons. Two recent studies
targeting the rostral forebrain confirmed by injection of
Fluoro-Gold or RetroBeads into the nucleus accumbens
(NAc) that GLP-1 immunoreactive neurons in the NTS
project to this area [19,20].www.sciencedirect.com
GLP-1 producing neurons in the brainstem Trapp and Richards 965Recently, Llewellyn-Smith and co-workers [21,22] have
revisited the expression pattern of PPG neurons with the
use of a transgenic mouse (PPG-YFP mouse) that
expresses YFP under the control of the glucagon promo-
ter [23]. These mice show strong YFP fluorescence
throughout the entire cytoplasm of the GLP-1 neurons
and thus allowed the researchers to map the PPG neurons
in mouse with unprecedented precision, showing not only
cell bodies and terminals, but also the entire dendritic
tree and axons [21,22]. These studies demonstrated
mouse PPG cell bodies in the caudal NTS, the inter-
mediate reticular formation mediodorsal of the nucleus
ambiguus and along the midline ventral of the hypoglos-
sal nucleus. Additionally, these mice have PPG neurons
in the lumbar sacral spinal cord [24] and the granule cell
layer of the olfactory bulb [25]. As has been suggested for
the olfactory bulb PPG neurons in rat, these appear to be
granule cells and thus local interneurons. Consequently,
it is expected also in mouse, that all PPG cell projections,
which are primarily to autonomic control areas, originate
from brainstem PPG neurons. Tracing studies in rat thus
far suggest no functional segregation between NTS and
reticular PPG neurons [15,18].
In the absence of reliable antibodies for the GLP-1 re-
ceptor, the targets for GLP-1 in the brain have been
mapped in rat either by identifying GLP-1 binding sites
[26] or by in situ hybridisation for GLP-1 receptor mRNA
[17]. GLP-1 receptors are found throughout the entire
rostrocaudal extent of the CNS, from the olfactory bulb
down to lamina 5–10 in the sacral spinal cord [17].
However, notable exceptions are cerebral cortex and
cerebellum which are devoid of GLP-1 receptors. Inter-
estingly, GLP-1 neurons do not project to these brain
structures in rat or mouse [10,14,22]. This good corre-
lation between the expression of GLP-1 receptors and the
presence of fibres from GLP-1-expressing neurons is also
seen at a regional level; for example, within hypothalamus
the arcuate nucleus receives many GLP-1-positive fibres
and expresses high levels of GLP-1 receptor, whereas the
neighbouring ventromedial nucleus has low levels of both
[17,22]. Similarly, Manton et al. [24] have recently
reported that GLP-1 axons are found throughout the
entire rostrocaudal extent of the ventral spinal cord in
the PPG-YFP mouse with the highest density of term-
inals in lamina X and the intermediolateral nucleus
(IML). These data correlate very well to the GLP-1
receptor expression pattern described by Merchenthaler
et al. [17] in rat.
However, whilst Merchenthaler et al. report a moderate
level of GLP-1 receptors within the caudal hippo-
campus of rat, no innervation of this area is seen in
mouse [22]. Given that effects of exogenous GLP-1
injection into the hippocampus have been observed
[27,28] this raises the question of whether these recep-
tors are activated under physiological conditions, and ifwww.sciencedirect.com so where would the GLP-1 originate from? One possible
origin could be microglia involved in the response to
inflammation of the brain. It has been reported that
activated microglia express GLP-1, at least in culture
[29]. The physiological relevance of this GLP-1 expres-
sion, though, remains to be established.
In conclusion, these anatomical findings suggest that
projections from PPG neurons are appropriately placed
to elicit effects on the vast majority of GLP-1 receptors
expressed in the CNS.
Central application of GLP-1 receptor antagonists to
explore the role of endogenous GLP-1 in brain
Most studies to date addressing the physiological role of
central GLP-1 receptors have employed intracerebroven-
tricular (i.c.v.) injections of high concentrations of GLP-1
or a GLP-1 receptor agonist. These studies have revealed
a plethora of responses, such as suppression of food
intake, improved blood glucose levels, nausea, increased
taste aversion, alterations in blood pressure and heart rate,
hypothermia, neuroprotection and effects on learning and
memory [15,28,30–35].
Whilst these studies demarcate the potential scope for
effects of endogenous GLP-1 released from PPG
neurons, the question remains, whether some of the
effects observed are due to supraphysiological concen-
trations of GLP-1 producing a pattern of GLP-1 receptor
activation that would not occur under physiological con-
ditions. This question is best addressed by the injection
of a GLP-1 receptor antagonist into brain in the absence
of any exogenous GLP-1 or GLP-1 analogue.
In their landmark paper, more than 15 years ago, Turton
and colleagues [36] demonstrated that not only does
i.c.v. injection of GLP-1 produce a reduction in food
intake in rat but also that i.c.v. injection of the truncated
exendin fragment (9–39; Ex9), a GLP-1 receptor antagon-
ist, strongly increased food intake and body weight in
satiated animals whilst having no effect on starved rats
[36,37] (see also [38]). This demonstrated not only a
physiological role for endogenous GLP-1, but also
showed that endogenous release varies with the animal’s
feeding state.
Several GLP-1 receptor antagonists [39] have been used
to explore the role of endogenous GLP-1 in brain. Most of
these studies have focused on food intake, showing that
central administration of GLP-1 receptor antagonists can
cause increased feeding in stressed animals, attenuate c-
fos expression in the brainstem and decrease LiCl-
induced anorexia and stress hormone levels [40–43].
Others have shown reduced glucose tolerance [44] or
impaired the insulin-dependent suppression of hepatic
glucose production [45] when central GLP-1 receptors
were blocked. However, whilst these studies indicate aCurrent Opinion in Pharmacology 2013, 13:964–969
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injection of these antagonists has precluded dissection of
the specific neuronal populations involved. To overcome
this limitation, several recent papers used site-specific
injections into the brain parenchyma to allow the exam-
ination of specific brain nuclei [19,20,38,46,47].
Delineating ascending pathways: injection of
antagonists into forebrain sites
Most of these studies have focused on the dissection of
GLP-1 effects on food intake. Schick et al. demonstrated
that lateral hypothalamic microinjections of Ex9 signifi-
cantly augmented food intake in satiated rats only [38].
More recent studies were designed to dissect suppression
of metabolically driven food intake from conditioned
taste aversion and from reward system driven appetite.
These papers explored the influence of the nucleus
accumbens (NAc) and the ventral tegmental area
(VTA) known to be involved with reward and motivation
[19,20,46,48] (Figure 1). Specific targeting of the NAc
core rather than the shell region with Ex9 was shown to
increase food intake up to 2 hours after animals entered
the dark phase of the circadian cycle [19]. Similarly, a
unilateral injection of Ex9 into the VTA increased high
fat diet intake in rats at 3 and 6 hours post-injection
[20]. Further analysis of the effects of GLP-1R block-
ade in the NAc core on the intake of palatable food
suggested that GLP-1 receptor activation in the NAc
affects meal size rather than meal frequency [46] whereas
the opposite was observed for GLP-1 receptor activation
in the hindbrain [47].
Descending pathways: injection of antagonists into
brainstem
Early evidence that hindbrain GLP-1 receptors are
involved in different aspects of food intake than those
in the hypothalamus was provided by Grill et al. [49] who
showed that lipopolysaccharide (LPS) anorexia is alle-
viated by blocking GLP-1 receptors accessible from the
4th, but not the 3rd, ventricle. Subsequently, it was shown
that both 4th ventricular and local caudal NTS delivery of
Ex9 increased food intake in satiated rats, indicating a
role for hindbrain GLP-1 receptors in ‘metabolic’ food
intake [47]. The same study also demonstrated that the
reduction in food intake caused by gastric distension is
reversed by 4th ventricular Ex9, but not when caused by
duodenal nutrient infusion [47]. These findings suggest
that it is unlikely to be duodenally released GLP-1
entering the brainstem that activates the GLP-1 recep-
tors, but rather electrical signals (presumably vagal) from
the stomach that activate PPG neurons in the NTS.
These in turn release GLP-1 locally, leading to the
observed effects (Figure 1).
At present, little is known about which cell types in the
lower brainstem express GLP-1 receptors, and thus what
downstream pathways are likely to be involved. A recentCurrent Opinion in Pharmacology 2013, 13:964–969 study has identified some of the cell types receiving close
appositions from PPG axons within the brainstem [21].
These include about 30% of cholinergic dorsal vagal
neurons, a similar proportion of catecholaminergic A1/
C1 and A2/C2 neurons, and the majority of serotonergic
neurons in the raphe pallidus and the parapyramidal tract.
These cell populations would provide both descending
and ascending projections that could potentially account
for effects on food intake, thermoregulation, blood pres-
sure, heart rate, insulin release, among others.
What inputs do GLP-1 neurons receive?
Until the development of the PPG-YFP mouse by
Reimann and colleagues [23], PPG neurons could only
be identified post hoc by immunocytochemistry. This
limited functional analysis of this cell population to the
use of immunoreactivity to c-fos or equivalent markers of
neuronal activation [15,50,51]. Such studies demon-
strated that PPG neurons were activated by gastric dis-
tension [51], leptin [52], LiCl and oxytocin [53], placing
the PPG neurons at the core of central GLP-1 effects
observed in relation to these stimuli.
The PPG-YFP mouse allowed identification of PPG
neurons in living tissue and in the first study that directly
recorded the electrical activity of GLP-1-expressing cells,
Hisadome and colleagues discovered that leptin directly
depolarises these neurones in the nucleus of the solitary
tract (NTS) and that, whilst these neurons do not express
GLP-1 receptors, at least a proportion of PPG neurons
receive monosynaptic input from the solitary tract [54]
(i.e. vagal afferent fibres). These results further supported
the notion that gut-derived GLP-1 would act in the
periphery, rather than directly on PPG neurons in order
to elicit central GLP-1 release (Figure 1). A recent study
on human subjects that had undergone truncal vagotomy
further supports this hypothesis [55]. Subsequently, Hisa-
dome et al. reported that CCK and noradrenaline
increased the activity of GLP-1-expressing neurons by
enhancing glutamatergic drive [56] (Figure 1). These
results demonstrated that GLP-1 neuronal activity is
modulated by both long-term and short-term satiety
signals. It now remains to be established whether there
is a separation of these neurons into discrete subpopu-
lations that responds to either short-term or long-term
signals, and similarly whether the projection targets for
the individual PPG neurons correlate with the specific
inputs they receive.
Can we interfere with the function of GLP-1 neurons in
vivo, and what are the consequences?
Finally, in order to unequivocally determine the import-
ance of the central GLP-1 system, it needs to be com-
pletely separated from the peripheral system. There are
two key questions to be answered. Firstly, are central
GLP-1 receptors only accessible for CNS derived GLP-1,
and secondly, do the hindbrain GLP-1 neurons fulfil thiswww.sciencedirect.com
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Physiologically relevant inputs to and projections from brainstem PPG neurons. Brainstem PPG neurons receive inputs (blue) related to short-term and
long-term energy status. Inputs include electrical satiety signals via the vagal nerve from the stomach and gut, hormonal signals like CCK from the gut,
or leptin from adipose tissue. Outputs (red) from these neurons are directed towards various forebrain sites with emphasis on food intake and glucose
control. Local and descending outputs from these neurons travel to dorsal vagal efferent neurons, serotonergic (5-HT) neurons and catecholaminergic
neurons in the NTS and ventrolateral medulla. These outputs might be involved in the regulation of blood glucose in the case of vagal neurons and
thermoregulation for 5-HT neurons. Additionally, there are strong direct projections from PPG neurons to sympathetic preganglionic neurons in the
central autonomic area (CAA) and the intermediolateral cell column (IML) in the spinal cord. ARC, arcuate nucleus; VTA, ventral tegmental area; DMH,
dorsomedial hypothalamus; PVN, paraventricular nucleus; NAc, nucleus accumbens; DMNX, dorsal motor nucleus of the vagus; CCK, cholecystokinin.role? The pharmacological studies employing the central
injection of GLP-1 receptor antagonists address these
questions only partially, because whilst they demonstrate
the action of endogenous GLP-1, they cannot rule out the
possibility that gut-derived GLP-1 is responsible for the
observed effects on central GLP-1 receptors. Similarly,
the global knockout of either the glucagon gene, or the
GLP-1 receptor gene, affects both central and peripheral
systems. Additionally, such a genetic approach is prone to
developmental compensation. To circumvent such pro-
blems, Barrera et al. [57] employed RNA interference,
delivered by stereotaxic injection of lentivirus into the
NTS, to knock down GLP-1 expression. With this
approach they achieved a reduction of preproglucagon
mRNA levels by 50% in NTS and by 30% in the PPG cell
terminals in PVN. They observed hyperphagia and
weight gain compared to control animals that received
injections of scrambled shRNA. However, these controlswww.sciencedirect.com only regained preoperative weight 28 days after surgery.
Nevertheless, these data indicate that endogenous GLP-
1 derived from PPG cells has a physiological role in the
regulation of energy balance and it is experiments like
these that will hopefully give us a more complete and
detailed picture of the physiological importance of the
PPG neurons over the coming years.
Conclusions
We suggest that the effects of neuropeptide GLP-1 (released
by PPG neurons) are distinct from the effects of incretin
GLP-1 (released by enteroendocrine cells) and that the
PPG neurons constitute a central signalling network that
integrates peripheral and central signals for both long and
short term nutritional and digestional status. GLP-1
neurons might produce an output signal to feeding and
autonomic circuits which optimises digestion and assim-
ilation of nutrients and regulates calorific intake.Current Opinion in Pharmacology 2013, 13:964–969
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